Loading stock…

Protagonist Therapeutics, Inc. (PTGX) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated today

Protagonist Therapeutics, Inc.

PTGXMarket cap $9.05BPrice $139.9

Country🇺🇸United States

SectorHealthcare

IndustryBiotechnology

Develops peptide-based drugs targeting hormone pathways to treat rare diseases and inflammatory disorders. Its partnership with Johnson & Johnson on a blockbuster ulcerative colitis drug shows big pharma is betting heavily on its pipeline.

In Bastion Portfolios?

52W Return+81%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+20%9

Revenue Forecast

Rev CAGR (1y)+1105%10

Rev CAGR (3y)+88%10

Rev CAGR (5y)+81%10

Earnings Forecast

EPS Growth Y+10%5

EPS Growth Y+2Loss1

EPS Growth Y+30%5

Quality

Margins

EBIT Margin21%8

Net Income Margin29%9

Free Cash Flow Margin46%10

Debt

Net Debt/EBITDA-13.510

Efficiency

ROE11%5

ROA10%9

Earnings Stability44

GEAR+VERY STRONG95

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)272

P/E Ratio (Forward 3y)591

P/BV10.82

EV Multiples

EV/EBITDA Fwd272

EV/EBIT Fwd263

Yield

Free Cash Flow Yield1.4%3

Dividend Yieldna–

Momentum

Short term

1 month return-4%5

3 month return+2%7

YTD return+60%10

Mid term

Price vs 52wHigh87%7

1 year return+109%10

Long term

3 year return+747%10

5 year return+667%10

Risk Shield

Price Risk

Beta-0.110

Volatility48%3

Free Cash Flow

Free Cash Flow Margin46%10

Free Cash Flow Yield1.4%3

Quality

ROCE8%4

Earnings Stability44

Net Debt/EBITDA-13.510

02Growth

Is it actually growing, and how fast?

PTGXProtagonist Therapeutics

Revenue FY25$46M

GROWTH RATING↗

VERY STRONG93 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+20%9

Revenue, next 1Y+1105%10

Revenue, next 3Y, CAGR+88%10

Revenue, next 5Y, CAGR+81%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26E0%5

EPS growth, FY27ELoss1

EPS growth, FY28E0%5

GROWTH ASSESSMENT

STRENGTHS

It out-grows 93% of companies worldwide.

Revenue grew 20%/yr over the last 3 years, ahead of 80% of companies worldwide.9/10

Revenue is set to grow 88%/yr over the next 3 years, ahead of most of the market.10/10

Revenue grew 20%/yr over the last 3 years and is set to grow 88%/yr from here.

The runway holds up: revenue is set to grow 81%/yr over five years.10/10

WATCH

None flagged.

WEAKNESSES

Earnings are set to fall even as revenue grows (EPS about 0%/yr vs revenue 88%/yr).

BOTTOM LINE

Reaccelerating Grower

A top-tier grower that's speeding up. The one thing to watch: earnings are forecast to fall.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY STRONG89 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-4%5

3-month return+2%7

YTD return+60%10

MID & LONG-TERM▾SCORE

% of 52-week high87%7

1-year return+109%10

3-year return+747%10

5-year return+667%10

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +747% over three years and +667% over five, ahead of 90% of the market.

It's up 109% over the past year, but 13% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over three months (+2%) and so far this year (+60%).

WATCH

Returns sit at the market level over the past month (-4%).

WEAKNESSES

None flagged.

BOTTOM LINE

Momentum Leader

Short- and long-term returns both rank among the best globally. The market is behind it — a core fit for momentum strategies.

04Value

Are you paying a fair price for it?

Stop guessing on Protagonist Therapeutics, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

PTGXProtagonist Therapeutics

Revenue FY25$46M

GROWTH RATING↗

VERY STRONG93 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+20%9

Revenue, next 1Y+1105%10

Revenue, next 3Y, CAGR+88%10

Revenue, next 5Y, CAGR+81%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26E0%5

EPS growth, FY27ELoss1

EPS growth, FY28E0%5

GROWTH ASSESSMENT

STRENGTHS

It out-grows 93% of companies worldwide.

Revenue grew 20%/yr over the last 3 years, ahead of 80% of companies worldwide.9/10

Revenue is set to grow 88%/yr over the next 3 years, ahead of most of the market.10/10

Revenue grew 20%/yr over the last 3 years and is set to grow 88%/yr from here.

The runway holds up: revenue is set to grow 81%/yr over five years.10/10

WATCH

None flagged.

WEAKNESSES

Earnings are set to fall even as revenue grows (EPS about 0%/yr vs revenue 88%/yr).

BOTTOM LINE

Reaccelerating Grower

A top-tier grower that's speeding up. The one thing to watch: earnings are forecast to fall.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY STRONG89 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-4%5

3-month return+2%7

YTD return+60%10

MID & LONG-TERM▾SCORE

% of 52-week high87%7

1-year return+109%10

3-year return+747%10

5-year return+667%10

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +747% over three years and +667% over five, ahead of 90% of the market.

It's up 109% over the past year, but 13% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over three months (+2%) and so far this year (+60%).

WATCH

Returns sit at the market level over the past month (-4%).

WEAKNESSES

None flagged.

BOTTOM LINE

Momentum Leader

Short- and long-term returns both rank among the best globally. The market is behind it — a core fit for momentum strategies.

04Value

Are you paying a fair price for it?

Stop guessing on Protagonist Therapeutics, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community